Bio-Techne buying 'liquid biopsy' firm Exosome for $250M+
June 26, 2018 at 08:30 AM EDT
Bio-Techne had agreed to buy Exosome Diagnostics, a Massachusetts company whose technology tests for disease by scanning body fluids, for $250 million in cash. But the deal could wind up being worth more than twice as much.
